Histological AND Immunohistochemical Study on the Effect of Stem Cell Therapy on Bleomycin Induced Pulmonary Fibrosis in Albino Rat

Marwa Mohammed Sabry, Seham Abd-Elhamed Elkalawy, Rahma Kamal El-din Abo-Elnour, Dalia Fathy Abd-El-Maksod

Department of Histology, Faculty of Medicine, Cairo University, Cairo, Egypt

Aim of work: To demonstrate the bleomycin induced histological changes in the lung and the possible protective and/or therapeutic effect of stem cell therapy.

Materials and methods: Study was carried out on 36 adult male albino rats, classified into 4 groups: group I (control), group II (bleomycin treated group), group III (early stem cell treated group: immediately after bleomycin), group IV (late stem cell treated group: 7 days after bleomycin). Sections were taken at the 14th day of experiment. stained with Hematoxylin and Eosin, Masson's trichrome, immunohistochimical stains for α-SMA & PCNA. Sections were examined by light & immunofluroscent microscopy. Area percent of collagen fibers, area percent & optical density of α-SMA immunopositive cells were measured as well as the number of H&E and PCNA stained pneumocytes type II was counted.

Results: Group II showed, thickening of septa, extravasation of blood, dividing pneumocytes type II cells with acinar formation, cellular infiltration, fibroblast cells, almost complete loss of normal lung architecture in certain fields, consolidation and replacement of the lung tissue with fibrous tissue in other fields. Restoring of lung tissue with significant decrease in mean area % of collagen fibers, α-SMA immunopositive cells were detected in group III.

Conclusions: Early treatment with bone marrow derived mesenchymal stem cells (BMSCs) immediately after bleomycin administration showed a significant reduction in fibrotic changes, however the late treatment with BMSCs (7 days) after bleomycin administration showed non significant results.

Keywords: Bleomycin-BMSCs- α-SMA-PCNA-Lung fibrosis-PKII26

Introduction

Idiopathic pulmonary fibrosis (IPF) is considered one of the most common fibrotic lung diseases (1). It is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause limited to the lungs and associated with histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) (2). Bleomycin is a chemotherapeutic antibiotic, produced by the bacterium “Streptomyces verticillus” (3). It is an anticancer drug that is used mainly in treatment of Hodgkin, non-Hodgkin lymphomas and testicular carcinoma (4).
Bleomycin reproduced typical features of the human interstitial lung fibrosis in the form of intra-alveolar buds, mural incorporation of collagen and obliteration of the alveolar space (5). Myofibroblasts are increased in pulmonary fibrosis and considered principal cells responsible for deposition of collagen and extracellular matrix in lung fibrosis (6). The list of cells from which myofibroblasts can derive has grown impressively during the last years. It includes local fibroblasts, epithelial cells, endothelial cells, smooth muscle cells, pericytes, hepatic perisinusoidal cells, mesenchymal stem cells, and bone marrow-derived cells known as fibrocytes (7). Alpha smooth muscle actin is considered a key marker for myofibroblasts (8). Its expression is increased in lung fibrosis and enhance fibroblast contractility (9). Proliferating cell nuclear antigen (PCNA) is highly conserved between species (10). It serves as a co-factor for DNA polymerase delta in S-phase, as well as during DNA synthesis. The temporal specificity of PCNA expression makes it an ideal marker for cell proliferation (11). Bleomycin was found to increase the expression of PCNA in lung epithelial cells (12) There is an increased evidence supporting the migratory, differentiative and reparative capacity of MSCs in experimental models of lung inflammation and fibrosis (13). They can engraft in injured lung and in some cases are thought to acquire epithelial characteristics (14). This also may explain the several properties of MSCs that include their differentiative, regenerative and migratory capacity, immunomodulation and paracrine activity with the secretion of angiogenic, anti-apoptotic and anti-inflammatory factors (15).

Materials and Methods

Drugs
Bleomycin hydrochloride (Nippon Kayaku, Japan), 15 mg powder per vial was given as a single daily intravenous dose (in the tail vein) of 10 mg/kg mouse/day dissolved in sterile saline for 5 consecutive days (6) and the dose was adjusted according to body weight of animal species according to the paget’s table (16).

Systemically injected MSC: 500,000 cells/150 μl in Dulbecco’s Phosphate Buffered Saline (DPBS, GIBCO, NY, USA) was injected via tail vein immediately after bleomycin injection (in group III) or seven days after bleomycin injection (in group IV) (17).

Animals: Thirty six adult male albino rats (200~220 g) were housed in Kasr ElAiny Animal House, Cairo University. divided into four main groups, each group was kept in a separate cage. Anaesthetized with intraperitoneal injection of 75 mg/kg ketamine (intraperitoneal), sacrificed and lungs were dissected out. Procedures were in accordance with institutional guidelines.

Experimental design

Group I: Control (n=6). injected intravenously with saline in tail vein, two rats sacrificed with each experimental group.

Group II: Bleomycin treated rats (n=10). Sacrificed on the 14th day from start of bleomycin injection.

Group III: Combined stem cell and bleomycin treated group (starting together) (n=10) sacrificed on the 14th day from the start of bleomycin injection.

Group IV: Bleomycin then stem cell (seven days after bleomycin treatment) treated group (n=10), sacrificed on the 14th day from the start of bleomycin injection.

Specimens taken and sectioning: Specimens fixed in 10% buffered formalin solution and processed for paraffin sections of 5~7 μm thickness, sections mounted on cana balsam coated slides in case of ordinary and special staining and poly-L-lysine coated and charged slides in case of immunostaining. Subjected to following

Histological stains: H&E. (18) & Masson’s trichrome stains for collagen fibers (19).

Immunohistochemistry: For α-SMA antibody and PCNA antibody supplied by NEOMARKER labvision as mouse monoclonal antibody. Anti α-SMA immunohistochemical staining was done according to Bancroft and Cook (20). Paraffin sections were deparaffinized in xylene

---

Table 1. Mean values of area percentage of collagen fibers, area percent & optical density of α-SMA immunopositive cells and mean number of H&E & PCNA stained pneumocyte type II cells in the studied groups

| Parameter                        | Group I (control) | Group II | Group III | Group IV |
|----------------------------------|-------------------|----------|-----------|----------|
| Mean area percentage of collagen fibers | 2.9±1.00          | 7.6*±1.29| 3.7±1.0   | 5.2*±0.84|
| Mean area Percentage of α-SMA immunopositive cells | 6.12±1.7          | 13.6*±1,5 | 7.2±1.5   | 9.1*±1.1 |
| Mean optical density of α-SMA immunopositive cells | 0.59±0.45         | 0.635±0.36 | 0.58±0.30 | 0.621±0.84|
| Mean number of H&E stained type II pneumocytes | 5.9±2.23          | 10.2*±2.57 | 6.3±2.8   | 7.3±4.0  |
| Mean number of PCNA immunostained type II pneumocytes | 5.3±2.00          | 9.4*±1.17 | 5.9±2.18  | 6.7±1.25 |
for 1–2 minutes and then rehydrated in descending grades of ethanol then brought to distilled water for 5 minutes. Sections were incubated in hydrogen peroxide for 30 minutes then rinsed in PBS (3 times, 2 minutes each). Each section was incubated for 60 minutes with 2 drops (=100 μl) of the primary antibody α-SMA antibody, a Mouse Monoclonal Antibody (Lab Vision Corporation laboratories, CA 94538, USA, catalogue number MS-113-R7). Slides were rinsed well in PBS (3 times, 2 min. each), incubated for 20 minutes with 2 drops of biotinylated secondary antibody for each section then rinsed well with PBS. Each section was incubated with 2 drops (100 μl) enzyme conjugate "Streptavidin-Horseradish peroxidase" for 10 minutes at room temperature then washed in PBS. Substrate-chromogen (DAB) mixture 2 drops was applied to each section and incubated at room temperature for 5–10 min. then rinsed well with distilled water. Slides were counterstained with hematoxylin, dehydrated and mounted. α-SMA +ve cells showed brown cytoplasmic deposits. Anti PCNA Immunohistochemical staining was done using PCNA Ab-1 (Clone PC10), a mouse monoclonal antibody (Lab Vision Corporation laboratories, CA 94539, USA, catalogue number MS-106-P). in the same way as α-SMA immunohistochemical staining. PCNA +ve cells showed brown nuclear deposits. All steps performed in a humidity chamber preventing drying of

![Fig. 1](image-url)
the tissues. Non-specific background elimination step was omitted.

**Isolation, culture and labeling of MSCs from rat bone marrow (21):** Bone marrow cells obtained from the long bones of 8 weeks old male albino rat by aspiration. Bones flushed with Dulbecco's Modified Eagle's medium (DMEM) (Sigma, USA, D5796) supplemented with 10% fetal bovine serum (FBS) (Sigma, USA, F6178). Bone marrow slowly layered over Ficoll-Hypaque (Sigma, USA, F8016) in a ratio of 2:1 in sterile conical tubes and was centrifuged (at 1200 rpm for 30 minutes at room temperature). The opaque layer containing mononuclear cells was aspirated and resuspended in complete culture medium supplemented with 1% penicillin-streptomycin (Sigma, USA, P4333). Cells incubated at 37°C in 5% humidified CO₂ for 14 days. Media changed every 3~4 days. When large colonies developed (80~90% confluence), cultures washed twice with phosphate buffer saline (PBS) (P5493, Sigma, USA) and cells trypsinized with 0.25% trypsin (Sigma, USA, T1426) in 1 ml Ethylene Diamine Tetra Acetate (EDTA) (Sigma, USA, E6758) for 5 minutes at 37°C. After centrifugation (at 2400 rpm for 20 minutes at room temperature), cell pellets were resuspended with serum-supplemented medium and incubated in 25 cm² culture flasks (Sigma, USA, C6356). The resulting cultures referred to as first-passage cultures. MSCs in culture were characterized by their plastic adhesiveness and fusiform shape (22).

![Fig. 2](image-url)
Morphometric Study

Data obtained using "Leica Qwin 500 C" image analyzer computer system Ltd. (Cambridge, England). The following parameters were measured: area percent of collagen fibers, area percent of \( \alpha \) SMA immunopositive cells, optical density of \( \alpha \) SMA immunopositive cells, number of pneumocytes type II cells/HPF, Number of PCNA immunostained pneumocytes type II cells/HPF.

**statistical analysis:** Mean, standard deviation and analysis of variance (ANOVA) were calculated using EXCEL and SPSS 16 software. statistically significant when p was <0.05 (23).

RESULTS

Characteristics of MSCs in culture: MSCs in culture had fibroblast-like morphology and they adhered to the tissue culture substrate within 24~48 h. They reached confluence within 7~14 days.

Histological results

Hematoxylin and Eosin stained lung sections: Control group revealed normal lung architecture (Fig. 1a). Group II, bleomycin treated rats revealed lost lung architecture in the form of consolidation of lung tissue, that was accompanied by many fibroblasts, dividing pneumocyte type II cells, mitotic figures, fluid exudates (Fig. 1b).

---

Fig. 3. (3a) A section in the lung of an albino rat (Control group), showing absence of \( \alpha \)-smooth muscle actin immunoreactivity within the lining cells of the alveoli (\( \alpha \)-SMA \( \times \)1,000). (3b) Another field in the lung of an albino rat (group II), showing positive \( \alpha \)-smooth muscle actin immunoreactivity within the cytoplasm of fibroblast cells (F) (\( \alpha \)-SMA \( \times \)1,000). (3c) A section in the lung of an albino rat (group III), showing very faint \( \alpha \)-smooth muscle actin immunoreactivity within the cytoplasm of pneumocyte type II cells (arrows with bifid end) (\( \alpha \)-SMA \( \times \)1,000). (3d) A section in the lung of an albino rat (group IV), showing positive \( \alpha \)-smooth muscle actin immunoreactivity within the cytoplasm of fibroblast cells (curved arrow) (\( \alpha \)-SMA \( \times \)1,000).
Group III revealed normal lung appearance (Fig. 1c). Group IV revealed consolidated tissue with fibroblast cells and some dividing pneumocyte type II cells that exhibited an acinar formation (Fig. 1d).

**Masson trichrome stained sections:** Sections of control group revealed normal collagen fibers distribution (Fig. 2a). Group II showed extensive collagen fibers deposition (Fig. 2b), group III showed minimal collagen fibers in the lung interstitium and around bronchioles (Fig. 2c). While group IV moderate collagen fibers deposition (Fig. 2d).

**α-smooth muscle actin stained lung section:** Sections of control group revealed absence of α-smooth muscle actin immunoreactivity within the lining cells of the alveoli (Fig. 3a). Group II revealed positive α-smooth muscle actin immunoreactivity detected within the cytoplasm of fibroblast cells (Fig. 3b). Group III revealed faint α-smooth muscle actin immunoreactivity within the cytoplasm of pneumocyte type II cells (Fig. 3c). Group IV revealed positive α-smooth muscle actin immunoreactivity within the cytoplasm of fibroblast cells (Fig. 3d).

**Proliferative cell nuclear antigen (PCNA) stained lung sections:** Sections of control revealed few positive PCNA immunoreactivity within nuclei of pneumocyte type II cells (Fig. 4a). Group II revealed numerous positive PCNA immunoreactivity within nuclei of pneumocyte type II cells and fibroblast cells (Fig. 4b). Group III revealed few positive PCNA immunoreactivity within nuclei of pneumocyte type II cells (Fig. 4c). Group IV revealed many

![Figures A, B, C, D](image-url)
positive PCNA immunoreactivity within nuclei of pneumocyte type II cells (Fig. 4d).

Detection of PKH26 labeled mesenchymal stem cells by fluorescent microscope in unstained lung sections: Immunofluorescent microscopic examination of lung unstained section revealed the appearance of red fluorescent PKH26 labeled MSCs within the lung interstitium in group III (Fig. 5a) and heavily distribution of red fluorescent PKH26 labeled MSCs within the consolidated lung interstitium in group IV (Fig. 5b).

Morphometric results: (Fig. 3 & Table)

I. Mean area percent of collagen fibers: The mean area percent of collagen fibers in Masson's trichrome stained sections in the control group was (2.9±1.0). It showed an increase in groups II & IV to reach (7.6±1.29) & (5.2±0.84) that was significantly increased when compared with group I & III. In group III it was (3.7±1.0) that showed non significant difference when compared with group I.

II. Mean values of area percent & optical density of α-SMA immunopositive cells: There was an increase in the mean area percent of α-SMA immunopositive cells stained sections in groups II & IV to reach (13.6±1.5) & (9.1±1.1) that was significantly increased when compared with group I & III. In group III it was (7.2±1.5) that showed non significant difference when compared with group I (6.12±1.7). On the other hand, the mean optical density of α-SMA immunopositive cells in the control group was (0.59±0.45) while in group II, III & IV was (0.635±0.36), (0.58±0.30) & (0.621±0.84) respectively with non significant difference when compared with the control group.

III. Mean number of pneumocyte type II cells in H&E as well as PCNA immunostained in the studied groups: In H&E stained sections the mean number of pneumocytes type II cells in the control group was (5.91±2.23). There was an increase in group II to reach (10.2±2.57) which showed a significant increase when compared with all studied groups. While the mean number of pneumocytes type II cells in group III & IV was (6.3±2.8) & (7.3±4.0) respectively which was statistically non significant when compared with the control group. On the other hand, regarding PCNA immunostained sections, the mean number of pneumocytes type II cells in the control group was (5.3±2.00). There was an increase in group II to reach (9.4±1.17) which showed a significant increase when compared with all studied groups. While the mean number of pneumocytes type II cells in group III & IV was (5.9±2.18) & (6.7±1.25) respectively which was statistically non significant when compared with the control group.

Discussion

The aim of this study is to demonstrate the bleomycin induced histological changes in the lung and the possible protective and/or therapeutic effect of stem cell therapy against these changes.

The present work showed that (I.V) administration of bleomycin at a dose of 7 mg/kg/day for five consecutive days followed by sacrificing rats at day 14 of experiment (in group II) produced an inflammatory reaction in the form of thickening of septa accompanied by an infiltration of the lung tissue with inflammatory cells such as macrophages and lymphocytes, rather than many observed fibroblasts. It could be assumed that the inflammatory cells especially macrophages and lymphocytes may play an important role in activation of such fibroblasts and subsequent fibrosis. These finding were concomitant with (24) who reported that bleomycin can promote acute cellular
inflammation in lung tissue as demonstrated by a strong influx of inflammatory cells such as macrophages and activation of fibroblasts. Group II showed a significant increase in the number of pneumocyte type II cells (AECII) in both H&E and PCNA immunostained sections when compared to both control group and group III. Acinar formation were detected in certain fields, this could be explained by an attempt of these cells to repair. This is in accordance with (25) who defined AECII as local progenitor cells that can accomplish epithelial repair and regeneration in the different regions along the respiratory tract. It could be suggested that these cells might be a source of the myofibroblasts. This suggestion could be supported by the work of (26) and (24) who reported that epithelial-mesenchymal transition (EMT) is the process by which an epithelial cell becomes a more motile mesenchymal cell.

Confirming results of section stained with H&E & Masson's trichrome stains, group II revealed a significant increase in the mean area percent of $\alpha$-SMA immunoreactive myofibroblast as compared to the control group & group III, which may be explained by the ability of bleomycin to increase the number of the myofibroblasts. In agreement with the previous finding, (27) found that bleomycin treatment significantly led to upregulation of pro-fibrotic genes such as $\alpha$-SMA, which is considered as a key marker for myofibroblasts.

Current work showed that early combination of stem cell therapy with bleomycin treatment (in group III) revealed normal lung appearance that may be a direct relieving effect of early stem cell therapy on bleomycin treatment. This was supported by non significant increase in the mean area percentage of both collagen fibers & $\alpha$-SMA immune positive myofibroblasts as well as the mean number of pneumocyte type II cells in both H&E and PCNA stained section in group III comparing with control. (17)
further added that early treatment with MSCs may produce antagonists to tumor necrosis factor or other cytokines that disrupt signal pathways reducing the extent of inflammation within the lung. This was evidenced in our study by large areas of undamaged tissue with normal alveolar architecture. (28) commented that acceleration of resolution of fibrosis is by epithelial restitution. (29) also stated that MSCs restore cytoskeletal reorganization in alveolar epithelial cells. Current work also showed that late combination of stem cell therapy with bleomycin treatment in group IV revealed a significant increase in the mean area % of collagen fibers and α-SMA immunoreactive myofibroblasts when compared with both control group and group III. This may due to non protective effect of late combined stem cell therapy. In agreement with (17) who reported that, delaying MSC administration by 7 days after BLM challenge has not significantly reduced the hydroxyproline and collagen content of the lung therefore it could be noted that delaying injection of MSCs did not inhibit engraftment but eliminated the ability of the cells to alter the course of disease progression. Therefore, MSCs may produce factors that impinge on molecules expressed early but not late during the course of BLM-induced injury. However, (30) reported that both early (1 day) and late (7 day) MSC administration after BLM challenge has significantly reduced the hydroxyproline and collagen content of the lung but they stated that the early treatment was more significant and effective than the late treatment.

Potential conflict of interest
The authors have no conflicting financial interest.

References

1. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol 2010;42:535-542
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Jokhoh T, Kim DS, King TE Jr, Kondoh Y, Myres J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzek SL, Schinemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
3. Jindal SK. Interstitial lung disease. In: Jindal SK, editor. Textbook of Pulmonary and Critical Care Medicine. 1st ed. New Delhi; St. Louis: JP Medical Ltd; 2011. 1174-1188
4. Bugaut H, Bruchard M, Berger H, Derangère V, Odoul L, Euvrard R, Ladoire S, Chalmin F, Végran F, Récé B, Apetoh L, Ghiringhelli F, Mignot G. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 2013;8:e65181
5. Zhao L, Wang X, Chang Q, Xu J, Huang Y, Guo Q, Zhang S, Wang W, Chen X, Wang J, Neferine, a bisbenzylisoquinoline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur J Pharmacol 2010;627:304-312
6. Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J, Kohno S. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004;24:57-65
7. Hinz B. Regenerative Medicine and Biomaterials for the Repair of Connective Tissues. 2010. p39-82.
8. Zhao R, Du L, Gunst SJ. Clinical and mechanical stimuli regulate collagen phosphorylation (Colifin-P) in tracheal smooth muscle (TSM) tissues. The FASEB Journal 2006; 20:A1241
9. Pilling D, Tucker NM, Gomer RH. Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol 2006;79:1242-1251
10. Zdunek M, Korobowicz E. Expression of PCNA in non-small cell lung cancer before and after treatment with cisplatin and vepeside. Pol J Pathol 2006;51:77-81
11. Scovassi AI, Prosperi E. Analysis of proliferating cell nuclear antigen (PCNA) associated with DNA. Methods Mol Biol 2006;314:457-475
12. Fukumoto J, Harada C, Kawaguchi T, Suetsugu S, Maeyama T, Inoshima I, Hamada N, Kukano K, Nakamashi Y. Amphiregulin attenuates bleomycin-induced pneumopathy in mice. Am J Physiol Lung Cell Mol Physiol 2010;298:L131-L138
13. Tzouveleakis I, Antoniadis A, Bouros D. Stem cell therapy in pulmonary fibrosis. Curr Opin Pulm Med 2011;17:368-373
14. Gimble JM, Giluk F, Bunnell BA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther 2010;1:19
15. Rodman DM. Proof-of-concept trials for lung stem cell therapy. Proc Am Thorac Soc 2008;5:731-735
16. Paget GE. And Barnes JM. Toxicity test In: Laurence DR, Bacharak AL, editors. Evaluation of drug activities: pharmacometrics. London: Academic press; 1964. 135
17. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003;100:8407-8411
18. Kiernan JA. Histological and histochemical methods: theory and practice. 3rd ed. London, New York & New Delhi: Arnold Publisher; 2001. 111-162.
19. Bancroft JD, Gamble M. Connective tissue stains. In: Bancroft JD, Gamble M, Theory and practice of histological
techniques. 6th ed. Edinburgh, London, Oxford, New York, Philadelphia, St Louis, Sydney, Toronto: Elsevier Health Sciences, Churchill Livingstone; 2008. 150

20. Bancroft JD, Cook HC. Immunocytochemistry. In: Bancroft JD, Cook HC. Manual of histological techniques and their diagnostic applications. 2nd ed. London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone, Edinburgh; 1994. 263-325

21. Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev 2004;13:436-448

22. Rochefort GY, Vaudin P, Bonnet N, Pages JC, Domenech J, Charbord P, Eder V. Influence of hypoxia on the domiciliation of mesenchymal stem cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies? Respir Res 2005;6:125

23. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res 2010;19:237-270

24. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784

25. Anversa P, Kajstura J, Leri A, Loscalzo J. Tissue-specific adult stem cells in the human lung. Nat Med 2011;17:1038-1039

26. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003;3:921-930

27. Kulkarni AA, Thatcher TH, Hsiao HM, Olsen KC, Kottmann RM, Morrissiette J, Wright TW, Phipps RP, Sime PJ. The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis. PLoS One 2013;8:e63798

28. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006;1:365-369

29. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010;285:26211-26222

30. Cui A, Dai HP, Dai JW, Pang BS, Niu SJ, Lü YP, Wang C. Effects of bone marrow mesenchymal stem cells on bleomycin induced pulmonary fibrosis in rats. Zhonghua Jie He Hu Xi Za Zhi 2007;30:677-682